`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`
`
`
`INNOPHARMA LICENSING, INC., INNOPHARMA LICENSING LLC,
`INNOPHARMA INC., INNOPHARMA LLC,
`MYLAN PHARMACEUTICALS INC., MYLAN INC., LUPIN LTD. and LUPIN
`PHARMACEUTICALS INC.
`Petitioner,
`
`v.
`
`SENJU PHARMACEUTICAL CO., LTD., BAUSCH & LOMB, INC., and
`BAUSCH & LOMB PHARMA HOLDINGS CORP.
`Patent Owner.
`
`
`
`Case IPR2015-00902 (Patent 8,669,290 B2)
` Case IPR2015-00903 (Patent 8,129,431 B2)1
`
`
`
`Filed: April 6, 2016
`
`PETITIONER’S MOTION TO SEAL
`
`
`1 A word-for-word identical paper has been filed in each proceeding identified in
`
`the heading. IPR2015-01871 has been joined with IPR2015-00903 and includes
`
`Petitioners Lupin Ltd. and Lupin Pharmaceuticals Inc. in addition to the parties
`
`identified above.
`
`
`
`
`
`
`
`Pursuant to 37 C.F.R. §§ 42.14 and 42.55 and Proposed Stipulated
`
`Protective Order (Paper 36 in IPR2015-00902; Paper 38 in IPR2015-00903)
`
`(“Proposed Stipulated Protective Order”), Petitioner hereby moves to seal
`
`Petitioner’s Response to Patent Owner’s Motion for Observation Regarding Cross-
`
`Examination of Reply Witnesses Dr. Paul A. Laskar, Ph.D. and Ivan T. Hofmann,
`
`CPA/CFF, CLP, filed concurrently herewith in IPR2015-00902 and IPR2015-
`
`00903.
`
`Petitioner’s Response to Patent Owner’s Motion for Observation contain or
`
`refer to information contained in the cross-examination transcripts of Dr. Laskar
`
`(EX2272) and Mr. Hofmann (EX2273), which have been designated as testimony
`
`subject to Fed. R. Evid. 615 under the Proposed Stipulated Protective Order by the
`
`Patent Owner, and also with respect to EX2273 has been designated as Protective
`
`Order Material under the Proposed Stipulated Protective Order by the Patent
`
`Owner.
`
`The record of an inter partes review proceeding, including documents and
`
`things, is made available to the public, except as otherwise ordered. 37 C.F.R. §
`
`42.14. Despite the default rule of public availability, the Board will seal
`
`confidential information for “good cause,” because it is necessary to “strike a
`
`balance between
`
`the public’s
`
`interest
`
`in maintaining a complete and
`
`
`
`1
`
`
`
`
`
`understandable file history and the parties’ interest in protecting truly sensitive
`
`information.” 37 C.F.R. § 42.54(a); 77 Fed. Reg. 48756, 48760 (Aug. 14, 2012).
`
`It is Petitioner’s understanding that information in the following documents
`
`has been designated as Protective Order Material or Fed. R. Evid. 615 Material by
`
`Patent Owner pursuant to the Proposed Stipulated Protective Order: EX2272
`
`(Transcript of the Testimony of Paul Laskar dated March 25, 2016) and EX2273
`
`(Transcript of the Testimony of Ivan T. Hofmann dated March 25, 2016).
`
`Petitioner has no independent basis for the aforementioned documents to be
`
`sealed and thus makes no assertion as to whether or not they contain confidential
`
`RESPECTFULLY SUBMITTED,
`
`ALSTON & BIRD LLP
`
`
`
`
`
`
`
`/Jitendra Malik/
`
`Jitendra Malik (Reg. No. 55823)
`Reg. No. 55823
`Alston & Bird LLP
`4721 Emperor Blvd., Suite 400
`Durham, NC 27703-8580
`jitty.malik@alston.com
`
`Lead Counsel for Petitioner
`
`
`2
`
`information.
`
`
`
`Date: April 6, 2016
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`CERTIFICATION OF SERVICE
`
`Pursuant to 37 C.F.R. §§ 42.6(e), 42.8(b)(4) and 42.105, the undersigned
`
`certifies that on the 6th day of April, 2016, a complete copy of the foregoing
`
`Petitioner’s Motion to Seal was served on counsel of record for the Patent Owner:
`
`Senju Pharmaceutical Co., Ltd., et al.
`
`Bryan C. Diner
`bryan.diner@finnegan.com
`
`Justin J. Hasford
`justin.hasford@finnegan.com
`
`Joshua L. Goldberg
`Joshua.goldberg@finnegan.com
`
`
`
`
`
`Respectfully submitted,
`
`Alston & Bird LLP
`
`By: /Jitendra Malik/
`
`Jitendra Malik, Ph.D.
`Reg. No. 55823
`Alston & Bird LLP
`4721 Emperor Blvd., Suite 400
`Durham, NC 27703-8580
`jitty.malik@alston.com
`
`Bryan Skelton, Ph.D.
`Reg. No. 50893
`Alston & Bird LLP
`4721 Emperor Blvd., Suite 400
`Durham, NC 27703-8580
`bryan.skelton@alston.com
`
`1
`
`
`
`Lance Soderstrom
`Reg. No. 65405
`Alston & Bird LLP
`90 Park Avenue
`15th Floor
`New York, NY 10016-1387
`lance.soderstrom@alston.com
`
`Hidetada James Abe
`Reg. No. 61,182
`Alston & Bird LLP
`333 South Hope Street
`16th Floor
`Los Angeles, CA 90071
`james.abe@alston.com
`
`Joseph M. Janusz
`Reg. No. 70396
`ALSTON & BIRD LLP
`101 S. Tryon Street, Suite 4000
`Charlotte, NC 28205
`Telephone: 704-444-1000
`Fax: 704-444-1111
`joe.janusz@alston.com
`
`Attorneys for Petitioners InnoPharma
`Licensing, Inc., InnoPharma Licensing
`LLC, InnoPharma Inc., InnoPharma
`LLC, Mylan Pharmaceuticals Inc., and
`Mylan Inc.
`
`
`
`Deborah H. Yellin (Reg. No. 45,904)
`Crowell & Moring LLP
`Intellectual Property Group
`1001 Pennsylvania Avenue, N.W.
`Washington, DC 20004-2595
`Telephone No.: (202) 624-2947
`Facsimile No.: (202) 628-5116
`DYellin@Crowell.com
`
`2
`
`
`
`
`
`
`
`
`
`Jonathan Lindsay (Reg. No. 45,810)
`Crowell & Moring LLP
`Intellectual Property Group
`3 Park Plaza, 20th Floor
`Irvine, CA 92614-8505
`Telephone No.: (949) 798-1325
`Facsimile No.: (949) 263-8414
`JLindsay@Crowell.com
`
`Shannon Lentz (Reg. No. 65,382)
`Crowell & Moring LLP
`Intellectual Property Group
`1001 Pennsylvania Ave, N.W.
`Washington, DC 20004-2595
`Telephone No.: (202)624-2897
`Facsimile No.: (202) 628-5116
`SLentz@Crowell.com
`
`Attorneys for Petitioners Lupin Ltd. and
`Lupin Pharmaceuticals, Inc. joined in
`IPR2015-00903
`
`
`3